Prosecution Insights
Last updated: April 19, 2026

Examiner: ANTHOPOLOS, PETER

Tech Center 1600 • Art Units: 1611 1617

This examiner grants 57% of resolved cases

Performance Statistics

57.3%
Allow Rate
-2.7% vs TC avg
550
Total Applications
+58.7%
Interview Lift
1296
Avg Prosecution Days
Based on 522 resolved cases, 2023–2026

Rejection Statute Breakdown

1.3%
§101 Eligibility
12.1%
§102 Novelty
40.7%
§103 Obviousness
28.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19304103 PHARMACEUTICAL COMPOSITIONS Non-Final OA CALLIDITAS THERAPEUTICS AB
19303799 PHARMACEUTICAL COMPOSITIONS Non-Final OA CALLIDITAS THERAPEUTICS AB
19195082 PHARMACEUTICAL COMPOSITIONS Non-Final OA CALLIDITAS THERAPEUTICS AB
18516382 COMPOSITIONS AND METHODS FOR SCARLESS WOUND HEALING IN DIABETES Non-Final OA Washington University
18278688 NEURAL CONTROL OF ADAPTIVE IMMUNITY Non-Final OA The Feinstein Institutes for Medical Research
18397407 ORAL AMPHETAMINE COMPOSITION Non-Final OA Adare Pharmaceuticals, Inc.
17273994 USE OF PLANT EXOSOMES FOR SHOWING MODULATING EFFECTS ON IMMUNE SYSTEM CELLS Final Rejection YEDITEPE UNIVERSITESI
18244569 LONG COVID MEDICATION AND METHOD OF TREATMENT Non-Final OA KIRSCHNER, ELLEN
18276761 YEAST GLUCANS, METHODS AND USES THEREOF Non-Final OA Amyris Bio Products Portugal, Unipessoal LDA
18345514 TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS Non-Final OA Perfuse Therapeutics, Inc.
18330912 ANTIBIOTIC ADJUVANTS FOR GRAM NEGATIVE BACTERIA Non-Final OA San Jose State University Research Foundation
18039255 COMPOSITION INCLUDING FRACTION OF SYZYGIUM FORMOSUM EXTRACT AS ACTIVE INGREDIENT Non-Final OA CARBOEXPERT INC.
18197292 ACETIC ACID AND HYPOCHLOROUS ACID COMPOSITIONS FOR TREATMENT OF BIOFILMS AND WOUND CARE Final Rejection WIAB Water Innovation AB
17970906 COMPOSITIONS AND METHODS FOR TREATING BIOFILMS Final Rejection WIAB WATER INNOVATION AB
18035640 POLYSACCHARIDES FOR USE IN TREATING SARS-COV-2 INFECTIONS Non-Final OA NDPD PHARMA, INC.
18154304 CONTROLLED RELEASE VACCINE FORMULATION Non-Final OA Phibro Animal Health Corporation
18000546 METHOD OF MAKING VIRUS-LIKE PARTICLE Final Rejection Icosavax, Inc.
17710929 COMPOSITIONS COMPRISING PLANT-DERIVED EXOSOME-LIKE NANOVESICLES OR EXOSOMES AND METHODS OF USE THEREOF Final Rejection Nutraceutical Wellness Inc.
17765156 Method and Composition for Increasing Muscle Protein Synthesis Final Rejection Aouatef Bellamine
17635655 METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR Non-Final OA UNIVERSITAET ULM

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month